Hermetica Superfood Encyclopedia
The Short Answer
Hypericin is a naturally occurring naphthodianthrone compound derived from St. John's Wort (Hypericum perforatum) that exerts antitumor and antiviral effects primarily through photoactivation, generating reactive oxygen species that induce apoptosis in abnormal cells. It also modulates monoamine oxidase (MAO-A and MAO-B) inhibition and influences serotonin, dopamine, and norepinephrine reuptake pathways.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordhypericin benefits
Synergy Pairings3
Hypericin — botanical close-up
Health Benefits
Origin & History
Natural habitat
Hypericin is a naturally occurring red naphthodianthrone pigment primarily extracted from Hypericum perforatum (St. John's wort), a perennial herb native to Europe, western Asia, and North Africa. It is isolated from the plant's flowers, leaves, and stems using ethanol or methanol extraction followed by chromatographic purification, yielding a compound characterized by its red color and strong fluorescence.
“Hypericin, as a marker compound in St. John's wort, has been used in European folk medicine since ancient Greece (Hippocrates, ~400 BCE) for wound healing, burns, and mood disorders, earning the name 'herb of light' for treating jaundice and depression. Traditional European Medicine documented its use in 16th-century herbals including Dioscorides' De Materia Medica for skin inflammations, neuralgia, and melancholy.”Traditional Medicine
Scientific Research
The Phase 3 FLASH RCT (PMID: 35857290) evaluated 169 adults with early-stage mycosis fungoides, demonstrating superior response rates with 0.25% hypericin ointment plus light therapy compared to placebo (16% vs 4%, P=.04), with responses improving to 49% after 18 weeks. A Phase 2 psoriasis trial (PMID: 20889234) showed significant improvement with twice-weekly PDT, while a Phase 1 HIV trial (PMID: 10075619) was halted due to severe phototoxicity in 48% of patients without virologic benefit.
Preparation & Dosage
Traditional preparation
Clinically studied as 0.25% synthetic hypericin ointment (HyBryte™) applied topically twice weekly for 6-18 weeks, activated by visible light (635 nm, 30-40 J/cm²) for mycosis fungoides. Oral doses of 0.05-0.5 mg/kg/day were tested but limited by phototoxicity. No standardized extract doses established for systemic use. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Hypericin is not a nutrient or food substance; it is a naphthodianthrone polycyclic quinone compound (molecular formula: C₃₀H₁₆O₈, molecular weight: 504.44 g/mol) naturally occurring as a bioactive secondary metabolite in Hypericum perforatum (St. John's Wort). It is not consumed for macronutrient, vitamin, or mineral content. Key biochemical characteristics: • Concentration in St. John's Wort: Typically 0.03–0.3% of dry weight in aerial parts, with highest concentrations in flower buds and petals (up to ~3 mg/g dry weight in dark glands). • Bioactive class: Photosensitizing naphthodianthrone; primary photoactive chromophore absorbing strongly at ~590 nm and ~545 nm (visible light). • Related compounds: Co-occurs with pseudohypericin (typically present at 2–4× higher concentration than hypericin in crude extracts), hyperforin, and various flavonoids (quercetin, rutin, hyperoside). • Oral bioavailability: Very low; plasma Cmax after single 600 mg St. John's Wort extract dose (containing ~0.12–0.34 mg hypericin) is approximately 1–14 ng/mL, with Tmax of 4–6 hours and elimination half-life of approximately 24–48 hours. Bioavailability is limited by poor aqueous solubility (<1.5 µg/mL at physiological pH), extensive protein binding (>95% albumin-bound), and photodegradation. • Solubility/stability: Highly lipophilic (logP ~6.4); soluble in DMSO, ethanol, and alkaline aqueous solutions; rapidly photodegraded under white light exposure; stable when stored in dark conditions. • Standardization note: Commercial St. John's Wort extracts are typically standardized to 0.1–0.3% total hypericins (hypericin + pseudohypericin). Topical pharmaceutical preparations (e.g., HyBryte/SGX301 for cutaneous T-cell lymphoma) use synthetic or purified hypericin at 0.25% concentration. • No caloric, protein, carbohydrate, fat, fiber, vitamin, or mineral content is attributed to hypericin as an isolated compound.
How It Works
Mechanism of Action
Hypericin absorbs visible and near-UV light (wavelengths 540–610 nm), triggering a Type I/II photochemical reaction that generates singlet oxygen and superoxide radicals, inducing mitochondrial-mediated apoptosis in targeted cells. It non-selectively inhibits monoamine oxidase A and B enzymes, reducing degradation of serotonin, dopamine, and norepinephrine, which contributes to its reported antidepressant-adjacent activity. Additionally, hypericin inhibits protein kinase C (PKC) and disrupts viral envelope integrity by intercalating into lipid membranes upon photoactivation, conferring broad antiviral properties against enveloped viruses.
Clinical Evidence
A Phase 3 randomized controlled trial (FLASH trial, PMID: 35857290) demonstrated a 16% overall response rate for topical hypericin photodynamic therapy versus 4% for placebo in early-stage mycosis fungoides (cutaneous T-cell lymphoma), establishing its first FDA-approved indication as Poteligeo adjunct therapy. A Phase 2 trial showed statistically significant psoriatic lesion reduction with twice-weekly topical hypericin application, though sample sizes were modest and larger confirmatory trials are needed. Antiviral studies remain largely in vitro or early-phase, with photoactivated hypericin showing nanomolar IC50 values against HIV and herpes simplex virus in cell culture but lacking robust human trial data. Overall, evidence is strongest for topical photodynamic oncology applications and preliminary for systemic antidepressant or antiviral use.
Safety & Interactions
Hypericin causes dose-dependent photosensitivity, with systemic oral intake at doses above 0.5 mg/day significantly increasing risk of phototoxic skin reactions, particularly in fair-skinned individuals exposed to UV light. It is a potent inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein when consumed as part of whole St. John's Wort extract, reducing plasma concentrations of cyclosporine, warfarin, antiretrovirals (especially indinavir), oral contraceptives, and SSRIs—though isolated hypericin has less established CYP induction compared to the co-constituent hyperforin. Combining hypericin with serotonergic drugs (SSRIs, SNRIs, triptans) raises the theoretical risk of serotonin syndrome due to additive MAO inhibition. Pregnancy and breastfeeding safety has not been established in controlled human studies, and use should be avoided in those scheduled for surgery due to potential bleeding and anesthetic interactions.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
St. John's wort extractHypericum perforatum extractRed pigment from St. John's wortNaphthodianthroneHerb of light extractHypericin photosensitizerSJW hypericinHyperici herba extract
Frequently Asked Questions
What is hypericin used for medically?
Hypericin is most clinically validated as a photosensitizing agent in topical photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides), where the FLASH Phase 3 trial reported a 16% response rate versus 4% placebo (PMID: 35857290). It is also being investigated for psoriasis, antiviral applications against enveloped viruses like HIV and HSV, and has historically been associated with antidepressant activity through MAO inhibition within St. John's Wort preparations.
Does hypericin cause photosensitivity?
Yes, hypericin is a well-documented photosensitizer that absorbs light at 540–610 nm and generates reactive oxygen species upon UV or visible light exposure, which is therapeutically useful in photodynamic therapy but clinically hazardous with unintended sun exposure. Oral doses exceeding 0.5 mg/day have been associated with phototoxic reactions including erythema, blistering, and dermatitis, especially in individuals with fair skin. Patients using hypericin topically or systemically are typically advised to avoid direct sunlight and UV-emitting devices for 24–72 hours post-administration.
How does hypericin differ from hyperforin in St. John's Wort?
Hypericin is a naphthodianthrone pigment primarily responsible for photodynamic and potential antiviral activity, along with contributing to MAO-A/B inhibition, while hyperforin is a phloroglucinol derivative that is considered the main antidepressant constituent, acting via inhibition of serotonin, dopamine, norepinephrine, GABA, and glutamate reuptake through sodium conductive pathways. Hyperforin is also the primary driver of CYP3A4 and P-glycoprotein induction causing clinically significant drug interactions, whereas isolated hypericin exerts less pronounced CYP induction. Standardized St. John's Wort extracts typically specify both hypericin (0.3%) and hyperforin (3–5%) content to differentiate therapeutic and interaction profiles.
What is the typical dosage of hypericin in clinical studies?
In the FLASH Phase 3 oncology trial, hypericin was formulated as a 0.25% topical gel applied twice weekly to affected skin lesions, with photodynamic light activation administered 24 hours post-application. For oral St. John's Wort standardized to 0.3% hypericin, common antidepressant study doses deliver approximately 0.9–1.8 mg hypericin per day (300–600 mg extract three times daily), though isolated hypericin supplements are less common than whole-extract preparations. No universally established safe oral dosage for isolated hypericin exists outside of whole-extract frameworks.
Can hypericin interact with antidepressants or SSRIs?
Yes, hypericin contributes to MAO-A and MAO-B inhibition, and when combined with SSRIs such as fluoxetine, sertraline, or paroxetine, there is a documented risk of serotonin syndrome characterized by hyperthermia, agitation, tachycardia, and neuromuscular abnormalities. The FDA and European Medicines Agency have issued warnings against combining St. John's Wort products (containing hypericin and hyperforin) with serotonergic drugs, tricyclic antidepressants, and MAO inhibitors. At least 10 case reports of serotonin syndrome have been documented with co-administration of St. John's Wort and SSRIs, and this combination should be strictly avoided.
What is the clinical evidence for hypericin in treating cutaneous T-cell lymphoma?
A Phase 3 trial called FLASH demonstrated that topical hypericin photodynamic therapy (PDT) achieved a 16% response rate in early-stage mycosis fungoides compared to just 4% with placebo, making it a promising therapeutic option for this skin condition. This represents one of the most significant clinical outcomes for hypericin in dermatologic oncology. The evidence suggests hypericin-PDT warrants further investigation as a non-systemic treatment for cutaneous lymphomas.
Is hypericin effective for psoriasis, and what does research show?
A Phase 2 clinical trial demonstrated that twice-weekly hypericin photodynamic therapy produced significant improvements in psoriatic lesions compared to placebo. The photodynamic mechanism of hypericin appears particularly effective for inflammatory skin conditions when combined with light activation. This evidence suggests hypericin-PDT may be a viable alternative or adjunctive therapy for moderate psoriasis cases.
Who should avoid hypericin supplementation or topical use?
Individuals with a history of photosensitivity disorders, those taking photosensitizing medications, or those unable to avoid sun exposure should exercise caution with hypericin, as it can increase skin photosensitivity. Pregnant and nursing women should avoid hypericin due to limited safety data and its systemic absorption potential. People with certain medications that interact with St. John's Wort (the primary source of hypericin) should consult healthcare providers before use.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w hypericin curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
